Literature DB >> 31879050

Wire guided localisation for targeted axillary node dissection is accurate in axillary staging in node positive breast cancer following neoadjuvant chemotherapy.

Rajesh Balasubramanian1, Catrin Morgan1, Elina Shaari2, Tibor Kovacs1, Sarah E Pinder3, Hisham Hamed1, Ali R Sever4, Ashutosh Kothari5.   

Abstract

AIM: This study investigated whether wire localisation of the histologically proven positive, clipped axillary lymph node (ALN) with subsequent targeted axillary dissection (TAD) following neoadjuvant chemotherapy (NACT) improves axillary staging in breast cancer.
MATERIALS AND METHODS: We performed a retrospective review of patients with primary breast cancer and core biopsy proven metastatic ALNs, that had an excellent nodal radiological response following NACT, treated at our centre between January 2016 and December 2018. The initial cohort of patients (Group 1) underwent sentinel lymph node biopsy (SLNB), with a minimum of three nodes were sampled. The subsequent cohort (Group 2) had a marker clip inserted in the metastatic ALN prior to NACT. This cohort underwent wire guided excision of the clipped node in addition to SLNB, with a minimum of three nodes sampled.
RESULTS: A total of 47 patients were identified. Group 1 comprised 22 patients with a sentinel lymph node (SLN) identification rate (IR) of 95%. 25 patients (Group 2) underwent wire guided clip location and the SLN IR was 100% with a 92% clipped node IR. Evidence of pathological complete response (pCR) in the clipped node was associated with pCR in other nodes.
CONCLUSION: Targeted axillary dissection is a feasible technique following excellent response to NACT in selected patients with limited volume ALN metastasis, at diagnosis. The identification of the positive ALN during surgery is vital and the IR can be improved by clipping the node prior to NACT and wire guided localisation at the time of surgery.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Breast cancer; Clipped axillary node; Neoadjuvant chemotherapy; Targeted dissection; Wire localisation

Year:  2019        PMID: 31879050     DOI: 10.1016/j.ejso.2019.12.007

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

Review 1.  Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review.

Authors:  Vivian Man; Ava Kwong
Journal:  Breast Cancer Res Treat       Date:  2021-02-21       Impact factor: 4.872

Review 2.  De-Escalating Axillary Surgery in Node-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.

Authors:  Sabine R de Wild; Janine M Simons; Marie-Jeanne T F D Vrancken Peeters; Marjolein L Smidt; Linetta B Koppert
Journal:  Breast Care (Basel)       Date:  2021-08-17       Impact factor: 2.860

Review 3.  Metal Nanoparticles for Photodynamic Therapy: A Potential Treatment for Breast Cancer.

Authors:  Liang Shang; Xinglu Zhou; Jiarui Zhang; Yujie Shi; Lei Zhong
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

4.  Targeted axillary biopsy and sentinel lymph node biopsy for axillary restaging after neoadjuvant chemotherapy.

Authors:  Gunay Gurleyik; Sibel Aydin Aksu; Fügen Aker; Kubra Kaytaz Tekyol; Eda Tanrikulu; Emin Gurleyik
Journal:  Ann Surg Treat Res       Date:  2021-06-01       Impact factor: 1.859

Review 5.  Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study.

Authors:  Maggie Banys-Paluchowski; Maria Luisa Gasparri; Jana de Boniface; Oreste Gentilini; Elmar Stickeler; Steffi Hartmann; Marc Thill; Isabel T Rubio; Rosa Di Micco; Eduard-Alexandru Bonci; Laura Niinikoski; Michalis Kontos; Guldeniz Karadeniz Cakmak; Michael Hauptmann; Florentia Peintinger; David Pinto; Zoltan Matrai; Dawid Murawa; Geeta Kadayaprath; Lukas Dostalek; Helidon Nina; Petr Krivorotko; Jean-Marc Classe; Ellen Schlichting; Matilda Appelgren; Peter Paluchowski; Christine Solbach; Jens-Uwe Blohmer; Thorsten Kühn
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.